Premium
Recent Advances in Cell Membrane‐Derived Biomimetic Nanotechnology for Cancer Immunotherapy
Author(s) -
Raza Faisal,
Zafar Hajra,
Zhang Shulei,
Kamal Zul,
Su Jing,
Yuan WeiEn,
Mingfeng Qiu
Publication year - 2021
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.202002081
Subject(s) - nanomedicine , immunotherapy , cancer immunotherapy , nanotechnology , biodistribution , cancer , cancer therapy , tumor microenvironment , materials science , medicine , nanoparticle , biology , microbiology and biotechnology , in vivo
Immunotherapy will significantly impact the standard of care in cancer treatment. Recent advances in nanotechnology can improve the efficacy of cancer immunotherapy. However, concerns regarding efficiency of cancer nanomedicine, complex tumor microenvironment, patient heterogeneity, and systemic immunotoxicity drive interest in more novel approaches to be developed. For this purpose, biomimetic nanoparticles are developed to make innovative changes in the delivery and biodistribution of immunotherapeutics. Biomimetic nanoparticles have several advantages that can advance the clinical efficacy of cancer immunotherapy. Thus there is a greater push toward the utilization of biomimetic nanotechnology for developing effective cancer immunotherapeutics that demonstrate increased specificity and potency. The recent works and state‐of‐the‐art strategies for anti‐tumor immunotherapeutics are highlighted here, and particular emphasis has been given to the applications of cell‐derived biomimetic nanotechnology for cancer immunotherapy.